EPHA2 and cancer: EphA2 could activate Wnt/beta‐catenin and Hippo signalling pathways, which in turn induced EMT and downstream signalling cascade, thus mediating tumour invasiveness and resistance to cancer therapeutics in gastric cancer.8, 11